CLL Information & Management Archives

May 20, 2022

ASH 2021: Real-World Disease Burden, Costs and Resource Utilization of Hospital-Based Care Among Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia: Disparities and Risk Factors

At the American Society of Hematology Annual Meeting and Exposition, ASH 2021, we learned that we are practicing medicine that is more expensive and provides poorer care to many non-white patients.

May 20, 2022

ASH 2021: Dr. Jennifer Woyach on Predicting Development of Richter’s Syndrome After Ibrutinib Treatment

Dr. Mato and Dr. Woyach discusses the results of a study looking at which features might predict the future development of Richter’s syndrome in patients treated with ibrutinib.

May 13, 2022

ASH 2021: Dr. Jennifer Woyach with an Update on Ibrutinib vs. Chemoimmunotherapy as a Frontline Treatment for Chronic Lymphocytic Leukemia

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Anthony Mato interviewed Dr. Jennifer Woyach. They discussed updated results from the Alliance A041202 trial, which now has longer-term follow-up data.

May 12, 2022

An Immunologist Reviews CLL/SLL Patients and Their Compromised Immunity

We discussed the nature of the immune deficiencies associated with CLL/SLL and how one might remediate a significant part of the problem.

May 6, 2022

Application of National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for CLL/SLL from the informCLL Real-World Registry

Discussion of preliminary results from an ongoing phase 1 clinical trial studying the safety and efficacy of novel BCL2 inhibitor BGB-11417 alone and in combination with the next-generation BTK inhibitor zanubrutinib.

May 6, 2022

ASH 2021: Age-Related Differences in the Informational Experiences and Needs of Patients with Lymphoma: Results from the 2020 Lymphoma Coalition Global Patient Survey

In this study presented at the American Society of Hematology Annual Meeting and Exhibition (ASH 2021), the authors compared the experience in 5 different age groups on the amount of information provided, how well the information was understood, and topics on which patients and caregivers needed more information.

April 29, 2022

ASH 2021: Dr. Constantine Tam on Novel BCL2 Inhibitor BGB-11417 For Patients with Relapsed/Refractory B-Cell Malignancies

April 28, 2022

Why Do These Matter in CLL: Long-term Data, Side-Effect Management, and Staying Healthy?

Recorded on April 28, 2022 Join CLL Society and PlatformQ Health for this on-demand educational session consisting of 3 chapters: Getting Up-to-Speed on New Data Managing Side Effects of BTK Inhibitors: What, When, How, and WhoTips to Stay on the Patient/Caregiver ‘A Game’ Jennifer Woyach, MD, professor at The

April 21, 2022

COVID-19 Vaccine Refusal and Fair Allocation of Scarce Medical Resources: Moving CLL/SLL and Other Immunocompromised Patients to the Top Tier

In a pandemic with scarce resources, governments, medical institutions, and healthcare providers have had to make decisions and/or policies about allocating potentially lifesaving therapies among the many outpatients who might benefit from them.

CLL Information & Management

ASH 2021: Real-World Disease Burden, Costs and Resource Utilization of Hospital-Based Care Among Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia: Disparities and Risk Factors

ASH 2021: Dr. Jennifer Woyach on Predicting Development of Richter’s Syndrome After Ibrutinib Treatment

ASH 2021: Dr. Jennifer Woyach with an Update on Ibrutinib vs. Chemoimmunotherapy as a Frontline Treatment for Chronic Lymphocytic Leukemia

An Immunologist Reviews CLL/SLL Patients and Their Compromised Immunity

Application of National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for CLL/SLL from the informCLL Real-World Registry

ASH 2021: Age-Related Differences in the Informational Experiences and Needs of Patients with Lymphoma: Results from the 2020 Lymphoma Coalition Global Patient Survey

ASH 2021: Dr. Constantine Tam on Novel BCL2 Inhibitor BGB-11417 For Patients with Relapsed/Refractory B-Cell Malignancies

Why Do These Matter in CLL: Long-term Data, Side-Effect Management, and Staying Healthy?

COVID-19 Vaccine Refusal and Fair Allocation of Scarce Medical Resources: Moving CLL/SLL and Other Immunocompromised Patients to the Top Tier

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT